Drug intelligence / Profile preview

Charis 1000

Development stage: Unknown
Lead developer: Ensol Biosciences
Modality: Peptides
Administration: Subcutaneous

Overview

Charis 1000 is a synthetic peptide developed by Ensol Biosciences for the treatment of various cancers. It acts as a TGF-β1 inhibitor and is currently in Phase I clinical trials for prostate cancer and triple-negative breast cancer.

Other names: Charis 1000Charis1000Charis-1000C 1KC1KC-1K

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on Charis 1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Charis 1000.

Explore the full profile